ClinicalTrials.gg
Not yet recruitingNCT07366450Updated Jan 26, 2026

High-Dose vs Standard Ergocalciferol for Vitamin D Normalization in Aggressive Non-Hodgkin Lymphoma

An interventional study of High-Dose Loading Ergocalciferol and Standard Weekly Ergocalciferol in Vitamin D 25-Hydroxylase Deficiency and Lymphoma Non-Hodgkin, sponsored by Phramongkutklao College of Medicine and Hospital. Not yet recruiting at 1 site in Thailand. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-01-26.

Sponsored by Phramongkutklao College of Medicine and Hospital · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 13 studies in Lymphoma, Non-Hodgkin with a site in Thailand — 2 open to participants now, 5 under way, 2 of them phase 3. Lymphoma, Non-Hodgkin · Thailand.

Planned enrollment
13th of 13
52 · median 338
Started
2026
the only one that year
No phase
Only one
of the 13
Registered
13th of 13
by date
Lead sponsor
1 of 13
Phramongkutklao College of Medicine and Hospital

Among the 13 studies in Lymphoma, Non-Hodgkin with a site in Thailand, this one is the 13th largest by planned enrollment, is the only one that started in 2026, is the only one with no phase, and was the 13th registered.

Lymphoma, Non-Hodgkin

2,289 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 283 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

2 of the 13 studies in Lymphoma, Non-Hodgkin with a site in Thailand are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Thailand have not opened yet or have stopped. Only those recruiting at a site in Thailand →

Who these studies take

Of the 241 Lymphoma, Non-Hodgkin studies recruiting now, 141 (59%) set no upper age limit and 77 (32%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Lymphoma, Non-Hodgkin with a site in Thailand, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate whether a high-intensity loading dose of ergocalciferol (vitamin D2) can normalize blood vitamin D levels more rapidly and safely than standard weekly dosing in patients with newly diagnosed aggressive non-Hodgkin lymphoma. The study will also assess the safety of both dosing strategies.

The main questions it aims to answer are:

  • Does a high-intensity loading dose of ergocalciferol lead to faster normalization of serum 25-hydroxyvitamin D levels compared with standard weekly dosing?
  • Are there differences in safety and adverse events between the two dosing strategies?

Researchers will compare a high-intensity loading dose regimen of ergocalciferol with a standard weekly dosing regimen to determine differences in vitamin D normalization and safety outcomes.

Participants will:

  • Be randomly assigned to receive either a high-intensity loading dose or a standard weekly dose of ergocalciferol (vitamin D2)
  • Receive standard first-line immunochemotherapy for aggressive non-Hodgkin lymphoma
  • Have blood tests to monitor vitamin D levels, calcium, phosphate, and safety parameters at scheduled visits
  • Be followed for treatment response, survival outcomes, and adverse events during and after therapy
03

Conditions studied

  • Vitamin D 25-Hydroxylase Deficiency
  • Lymphoma Non-Hodgkin

Keywords

  • Non-Hodgkin lymphoma
  • Vitamin D deficiency
  • Overall survival
  • Efficacy
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 20 years.
  • Newly diagnosed aggressive non-Hodgkin lymphoma, confirmed by histopathological examination according to the WHO Classification of Haematolymphoid Tumours, 5th edition, with an indication for standard chemoimmunotherapy
  • (ECOG) performance status of 0-3.
  • Serum 25-hydroxyvitamin D level \< 30 ng/mL within 14 days prior to randomization.
  • Adequate organ function to receive full-dose standard chemotherapy.
  • Ability to provide written .

Exclusion criteria

Exclusion Criteria:

  • Mild hypercalcemia (corrected Ca > 10.4 mg/dL)
  • Hyperphosphatemia (PO4 > 4.5 mg/dL)
  • History of urolithiasis associated with hypercalciuria or a diagnosis of primary hyperparathyroidism.
  • Chronic kidney disease stage 4 or higher (estimated [eGFR] \< 30 mL/min/1.73 m²).
  • Inability to take oral medication, active gastrointestinal bleeding, or malabsorption syndrome.
  • Pregnancy or breastfeeding.
  • Prior systemic therapy for lymphoma.
  • Ongoing tumor lysis syndrome requiring urgent treatment.
  • Prior use of vitamin D supplements (ergocalciferol or cholecalciferol).

Withdrawal Criteria:

  • Development of mild hypercalcemia.
  • Development of mild hypophosphatemia.
  • Development of hypervitaminosis D.
  • Occurrence of severe adverse events (AEs) or side effects for which the investigator considers discontinuation of the study drug necessary for patient safety.
  • Investigator's judgment that continued participation may pose a safety risk, such as the occurrence of serious infection, febrile neutropenia, or organ failure.
  • Non-adherence to study medication, defined as cumulative vitamin D₂ intake of less than 80% of the expected cumulative dose at the time of serum vitamin D assessment.
  • Participant withdrawal of consent to continue participation in the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
52 participants (estimated)

Study arms

  • Experimental
    High-Dose Loading Ergocalciferol

    Participants receive a high-dose loading regimen of ergocalciferol (vitamin D₂) for rapid normalization of serum vitamin D levels, in combination with standard first-line chemoimmunotherapy for aggressive non-Hodgkin lymphoma.

    Drug: High-Dose Loading Ergocalciferol

  • Active comparator
    Standard Weekly Ergocalciferol

    Participants receive standard weekly dosing of ergocalciferol (vitamin D₂) for vitamin D normalization, in combination with standard first-line chemoimmunotherapy for aggressive non-Hodgkin lymphoma.

    Drug: Standard Weekly Ergocalciferol

Interventions

  • DrugHigh-Dose Loading Ergocalciferol

    Dose and Schedule: * Loading phase: Ergocalciferol 20,000 IU orally once daily (1 capsule per dose), administered 1-2 hours before breakfast, for 7 consecutive days. * Intensified phase: Following the loading phase, ergocalciferol 20,000 IU orally three times per week (Monday, Wednesday, and Friday) for a total treatment duration of 6 weeks from the first dose. * Maintenance phase: After completion of the initial 6-week treatment period, ergocalciferol 20,000 IU orally once weekly (Monday) until completion of lymphoma treatment. * Maximum duration of vitamin D₂ administration: Up to 18 weeks from the first dose of ergocalciferol. Thereafter, vitamin D dosing may be adjusted at the discretion of the treating physician.

  • DrugStandard Weekly Ergocalciferol

    Dose and Schedule: * Standard phase: Ergocalciferol 20,000 IU orally three times per week (Monday, Wednesday, and Friday), administered as 1 capsule per dose, 1-2 hours before breakfast, for a total duration of 6 weeks from the first dose. * Maintenance phase: After completion of the 6-week standard dosing period, ergocalciferol 20,000 IU orally once weekly (Monday) until completion of lymphoma treatment. * Maximum duration of vitamin D₂ administration: Up to 18 weeks from the first dose of ergocalciferol. Thereafter, vitamin D dosing may be adjusted at the discretion of the treating physician.

06

What researchers measure

Primary outcomes

  1. Proportion of Participants Achieving Vitamin D Normalization by Day 21

    Vitamin D normalization is defined as a serum 25-hydroxyvitamin D level ≥ 30 ng/mL. This outcome is assessed as a binary outcome (yes/no).

    Time frame: Day 21 (± 3 days) after the first dose of study medication

Secondary outcomes

  1. Event-Free Survival (EFS)

    Event-free survival is defined as the time from randomization to the first occurrence of disease progression, relapse after response, initiation of new lymphoma therapy, or death from any cause.

    Time frame: Up to 3 years

  2. Progression-Free Survival (PFS)

    Progression-free survival is defined as the time from randomization to the first documented disease progression according to the Lugano 2014 criteria or death from any cause, whichever occurs first.

    Time frame: Up to 3 years

  3. Overall Survival (OS)

    Overall survival is defined as the time from randomization to death from any cause.

    Time frame: Up to 3 years

  4. Best Overall Response (BOR)

    Best overall response is defined as the best response achieved after completion of first-line immunochemotherapy, including complete response (CR) or partial response (PR), as assessed by PET-CT or CT scan according to the Lugano 2014 criteria.

    Time frame: Through the completion of first-line immunochemotherapy, approximately 24 weeks

  5. Change in Serum 25-Hydroxyvitamin D Level

    Changes in serum 25-hydroxyvitamin D levels will be compared between study arms and summarized as absolute change and central tendency measures (mean or median).

    Time frame: Day 21 (± 3 days), Day 42 (± 3 days), Day 63 (± 3 days), and Day 126 (± 3 days) (end of treatment)

  6. Incidence of Grade ≥ 3 Infections

    Incidence of infections graded ≥ 3 according to the Common Terminology Criteria for Adverse Events (CTCAE), version 6.0.

    Time frame: From randomization through 30 days after the last dose of study treatment, approximately 22 weeks

  7. Safety and Treatment-Related Toxicity

    Safety and toxicity will be assessed based on the incidence of hypercalcemia, hypophosphatemia, and other adverse events, graded according to CTCAE version 6.0.

    Time frame: From randomization through 30 days after the last dose of study treatment, approximately 22 weeks

07

Study locations

1 site
  • Phramonkutklao Hospital
    Bangkok, 10400, Thailand
    • Tanapun Thamgrang, MD · Contacttanapun.tham@pcm.ac.th · 66859930142
    • Tanapun Thamgrang, MD · Principal investigator
    • Napakrit Tanpumiprated, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared due to institutional policy and privacy concerns. Only aggregate data may be shared upon reasonable request.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2026; primary completion for Dec 2028, 34 months later.

Of 60 non-industry interventional studies with no phase under Lymphoma, Non-Hodgkin, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 113. This study's planned 34 months is below that.

Counting every sponsor, half of 66 studies reached it within 43 months; a quarter within 22 and three quarters within 113.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2026
First posted
Jan 26, 2026
StartEst.
Feb 1, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Jul 31, 2029
Last update
Jan 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07366450
Lead sponsor
Phramongkutklao College of Medicine and Hospital
Responsible party
Sponsor
First posted
Jan 26, 2026
Start date
Feb 1, 2026 (estimated)
Primary completion
Dec 31, 2028 (estimated)
Completion
Jul 31, 2029 (estimated)
Last update
Jan 26, 2026

Study contacts

Tanapun Thamgrang, MD
Contact
tanapun.tham@pcm.ac.th
66859930142
Napakrit Tanpumiprated, MD
Contact
napakrich@hotmail.com
66881565102
Tanapun Thamgrang
principal investigator · Division of Hematology, Department of Medicine, Phramongkutklao Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion